No Yes Ok

Archive

« Older Entries Newer Entries »

Nexstim’s stroke therapy on CBS Wednesday, April 15th, 2015
   [...]
arGEN-x N.V. Announces Changes to the Board of Directors Tuesday, April 14th, 2015
Breda, The Netherlands / Ghent, Belgium, April 14, 2015 - arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for [...]
Merus reaches pivotal milestone in bispecific antibody collaboration with ONO PHARMACEUTICAL CO., LTD. Wednesday, April 8th, 2015
- Successful product lead identification underscores the strength of Merus’ platform in delivering human, full-length IgG bispecific antibodies -   Utrecht, The Netherlands, 8th April 2015 - Merus B.V., a l [...]
BioCapital Europe Company of the Year award goes to Prosensa Thursday, March 26th, 2015
Amsterdam, March 26, 2015. At the BioCapital Europe conference being held today in Amsterdam, Hans Schikan, CEO Prosensa, was presented with the BioCapital Company of the Year award by Martijn Kleijwegt, Managing Part [...]
Affimed Announces Financial Results for Fourth Quarter and Year End 2014 Wednesday, March 25th, 2015
--Transformative Year for the Company and its Bi- and Trispecific Cancer Immunotherapies--   Heidelberg, Germany, March 25, 2015 - Affimed N.V. (Nasdaq: AFMD), a clinical-stage biopharmaceutical company devel [...]
Affimed Completes TandAb Development Candidate Activities Meeting Amphivena's and Janssen's Criteria and Achieves Milestone Ahead of Schedule Tuesday, March 24th, 2015
-- Cancer Immunotherapy Development Candidate Selection Triggers Milestone Payment --   Heidelberg, Germany, March 24, 2015 - Affimed N.V. (Nasdaq: AFMD), a clinical-stage biopharmaceutical company developing [...]
LSP invests in Cardiac Dimensions, a pioneer in heart failure treatment Friday, March 13th, 2015
Amsterdam, the Netherlands, March 13 2015. LSP (Life Sciences Partners), a leading European investor in health care, announces its investment in Cardiac Dimensions, a private company commercializing the Carillon M [...]
Are we becoming allergic to our planet? Friday, March 13th, 2015
Over the past 50 years rapid technological advances and rising standards of living have transformed our lives beyond recognition. But could it be that this frenetic pace of change is linked to the dramatic increase in [...]
Curetis Initiates Clinical CE Performance Evaluation of Unyvero P55 Pneumonia Application Monday, March 9th, 2015
Clinical study to test more than 400 patient samples  Follows successful completion of analytical CE Performance Evaluation in more than 400 cartridge runs Expected results and product launch in sprin [...]
Probiodrug announces enrolment of first patient in Phase 2 Study of novel Treatment for Alzheimer’s disease Monday, March 9th, 2015
First patient enrolled at leading Alzheimer Center in Amsterdam   HALLE/SAALE, Germany, 09 March 2015 – Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel therapeutic solu [...]

« Older Entries Newer Entries »

2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
back to archive overview
Follow us

No Yes Ok

Archive

« Older Entries Newer Entries »

Nexstim’s stroke therapy on CBS Wednesday, April 15th, 2015
   [...]
arGEN-x N.V. Announces Changes to the Board of Directors Tuesday, April 14th, 2015
Breda, The Netherlands / Ghent, Belgium, April 14, 2015 - arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for [...]
Merus reaches pivotal milestone in bispecific antibody collaboration with ONO PHARMACEUTICAL CO., LTD. Wednesday, April 8th, 2015
- Successful product lead identification underscores the strength of Merus’ platform in delivering human, full-length IgG bispecific antibodies -   Utrecht, The Netherlands, 8th April 2015 - Merus B.V., a l [...]
BioCapital Europe Company of the Year award goes to Prosensa Thursday, March 26th, 2015
Amsterdam, March 26, 2015. At the BioCapital Europe conference being held today in Amsterdam, Hans Schikan, CEO Prosensa, was presented with the BioCapital Company of the Year award by Martijn Kleijwegt, Managing Part [...]
Affimed Announces Financial Results for Fourth Quarter and Year End 2014 Wednesday, March 25th, 2015
--Transformative Year for the Company and its Bi- and Trispecific Cancer Immunotherapies--   Heidelberg, Germany, March 25, 2015 - Affimed N.V. (Nasdaq: AFMD), a clinical-stage biopharmaceutical company devel [...]
Affimed Completes TandAb Development Candidate Activities Meeting Amphivena's and Janssen's Criteria and Achieves Milestone Ahead of Schedule Tuesday, March 24th, 2015
-- Cancer Immunotherapy Development Candidate Selection Triggers Milestone Payment --   Heidelberg, Germany, March 24, 2015 - Affimed N.V. (Nasdaq: AFMD), a clinical-stage biopharmaceutical company developing [...]
LSP invests in Cardiac Dimensions, a pioneer in heart failure treatment Friday, March 13th, 2015
Amsterdam, the Netherlands, March 13 2015. LSP (Life Sciences Partners), a leading European investor in health care, announces its investment in Cardiac Dimensions, a private company commercializing the Carillon M [...]
Are we becoming allergic to our planet? Friday, March 13th, 2015
Over the past 50 years rapid technological advances and rising standards of living have transformed our lives beyond recognition. But could it be that this frenetic pace of change is linked to the dramatic increase in [...]
Curetis Initiates Clinical CE Performance Evaluation of Unyvero P55 Pneumonia Application Monday, March 9th, 2015
Clinical study to test more than 400 patient samples  Follows successful completion of analytical CE Performance Evaluation in more than 400 cartridge runs Expected results and product launch in sprin [...]
Probiodrug announces enrolment of first patient in Phase 2 Study of novel Treatment for Alzheimer’s disease Monday, March 9th, 2015
First patient enrolled at leading Alzheimer Center in Amsterdam   HALLE/SAALE, Germany, 09 March 2015 – Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel therapeutic solu [...]

« Older Entries Newer Entries »

2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
back to archive overview
X

MONTHLY REPORTS

Here you can subscribe for the monthly report of the LSP Life Sciences Fund